Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ahmed Lasfar

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
HPB : the Official Journal of the International Hepato Pancreato Biliary Association|March 12, 2008
Pentoxifylline inhibits liver expression of tumor necrosis factor alpha mRNA following normothermic ischemia-reperfusionAlaa El-Ghoneimi, Raffaele Cursio, Annie Schmid-Alliana, et al.
Immunology|March 7, 2014
Critical role of the endogenous interferon ligand-receptors in type I and type II interferons responseAhmed Lasfar, Jeffry R Cook, Karine A Cohen Solal, et al.
Cancer Immunology, Immunotherapy : CII|March 11, 2010
Antitumor activity of type I and type III interferons in BNL hepatoma modelWalid Abushahba, Murugabaskar Balan, Ismael Castaneda, et al.
Pigment Cell & Melanoma Research|April 12, 2011
Constitutive Smad linker phosphorylation in melanoma: a mechanism of resistance to transforming growth factor-β-mediated growth inhibitionKarine A Cohen-Solal, Kim T Merrigan, Joseph L-K Chan, et al.
Plos One|October 19, 2012
Non-canonical Smads phosphorylation induced by the glutamate release inhibitor, riluzole, through GSK3 activation in melanomaWalid Abushahba, Oyenike O Olabisi, Byeong-Seon Jeong, et al.
Oncotarget|July 1, 2016
Concerted action of IFN-α and IFN-λ induces local NK cell immunity and halts cancer growthAhmed Lasfar, Andrew de laTorre, Walid Abushahba, et al.
Cancer Research|April 19, 2006
Characterization of the mouse IFN-lambda ligand-receptor system: IFN-lambdas exhibit antitumor activity against B16 melanomaAhmed Lasfar, Anita Lewis-Antes, Sergey V Smirnov, et al.
Cancer Letters|March 25, 2014
RUNX2 is overexpressed in melanoma cells and mediates their migration and invasionRajeev K Boregowda, Oyenike O Olabisi, Walid Abushahba, et al.
Oncotarget|April 23, 2016
The transcription factor RUNX2 regulates receptor tyrosine kinase expression in melanomaRajeev K Boregowda, Daniel J Medina, Elke Markert, et al.
Journal for Immunotherapy of Cancer|July 11, 2023
Combination oncolytic virus, radiation therapy, and immune checkpoint inhibitor treatment in anti-PD-1-refractory cancerSachin R Jhawar, Shang-Jui Wang, Aditya Thandoni, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
HPB : the Official Journal of the International Hepato Pancreato Biliary Association|March 12, 2008
Pentoxifylline inhibits liver expression of tumor necrosis factor alpha mRNA following normothermic ischemia-reperfusionAlaa El-Ghoneimi, Raffaele Cursio, Annie Schmid-Alliana, et al.
Immunology|March 7, 2014
Critical role of the endogenous interferon ligand-receptors in type I and type II interferons responseAhmed Lasfar, Jeffry R Cook, Karine A Cohen Solal, et al.
Cancer Immunology, Immunotherapy : CII|March 11, 2010
Antitumor activity of type I and type III interferons in BNL hepatoma modelWalid Abushahba, Murugabaskar Balan, Ismael Castaneda, et al.
Pigment Cell & Melanoma Research|April 12, 2011
Constitutive Smad linker phosphorylation in melanoma: a mechanism of resistance to transforming growth factor-β-mediated growth inhibitionKarine A Cohen-Solal, Kim T Merrigan, Joseph L-K Chan, et al.
Plos One|October 19, 2012
Non-canonical Smads phosphorylation induced by the glutamate release inhibitor, riluzole, through GSK3 activation in melanomaWalid Abushahba, Oyenike O Olabisi, Byeong-Seon Jeong, et al.
Oncotarget|July 1, 2016
Concerted action of IFN-α and IFN-λ induces local NK cell immunity and halts cancer growthAhmed Lasfar, Andrew de laTorre, Walid Abushahba, et al.
Cancer Research|April 19, 2006
Characterization of the mouse IFN-lambda ligand-receptor system: IFN-lambdas exhibit antitumor activity against B16 melanomaAhmed Lasfar, Anita Lewis-Antes, Sergey V Smirnov, et al.
Cancer Letters|March 25, 2014
RUNX2 is overexpressed in melanoma cells and mediates their migration and invasionRajeev K Boregowda, Oyenike O Olabisi, Walid Abushahba, et al.
Oncotarget|April 23, 2016
The transcription factor RUNX2 regulates receptor tyrosine kinase expression in melanomaRajeev K Boregowda, Daniel J Medina, Elke Markert, et al.
Journal for Immunotherapy of Cancer|July 11, 2023
Combination oncolytic virus, radiation therapy, and immune checkpoint inhibitor treatment in anti-PD-1-refractory cancerSachin R Jhawar, Shang-Jui Wang, Aditya Thandoni, et al.
Pageof 3